June 8, 2021 – Ortho Clinical Diagnostics (Raritan, NJ) announced its semi-automated ORTHO OPTIX Reader received FDA clearance on March 11, 2021, and is now available in the United States and Puerto Rico.
When paired with the ORTHO Workstation, the ORTHO OPTIX Reader provides a complete semi-automated testing platform for transfusion labs with low- to mid-volume throughput. The ORTHO OPTIX Reader has been shown to deliver 99.9% concordance, demonstrated by the award-winning fully automated ORTHO VISION Swift Platform.
The concordant and high-resolution images of the ORTHO OPTIX Reader help to support the technologist during remote review of results from across the laboratory. It also offers larger volume labs and healthcare networks a way to back-up or scale up their operations without having to invest in an additional full-automation analyzer.
The ORTHO OPTIX Reader’s high-resolution camera captures color, grayscale, front and back images of each test without operator intervention, which provides objective data for automated results interpretation and eliminates the subjectivity and discrepancies associated with human reading of results.
The ORTHO OPTIX Reader leverages the same ORTHO ID-MTS Gel card Technology as the ORTHO VISION Swift Platform and a comprehensive testing menu.
When connected to the customer’s laboratory information system, column grades and images can be automatically sent for long-term retention of result interpretations, therefore reducing and/or eliminating the need for manual documentation of results.
The system audit log and reporting module enhances traceability and reporting capabilities to keep labs compliant with accreditations and regulations. It also utilizes best-in-class ID-MTS Gel Card technology which offers a comprehensive testing menu to help standardize lab practices.